Long-term changes in serum cholesterol level does not influence the progression of coronary calcification

Cardiac Rehabilitation Institute, the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
International journal of cardiology (Impact Factor: 6.18). 03/2010; 150(2):130-4. DOI: 10.1016/j.ijcard.2010.03.001
Source: PubMed

ABSTRACT A number of reports controversially describe the influence of cholesterol level and lipid-lowering treatment (LLT) on the progression of coronary calcium (CC). We tested the hypothesis that long-term changes in serum cholesterol (CL) would affect the progression of CC.
The study population comprised 510 patients with stable angina pectoris, mean age of 63 ± 9 years. At baseline 372 patients received statin and/or fibrate (LLT group) while 138 patients did not (No-LLT at baseline group). Spiral CT every 24 months was used to track the progression of CC over a median 5.6 year follow-up.
CL decreased during follow-up in both groups, but more pronouncedly in patients with LLT. The changes in total calcium score (TCS) were similar in both groups (p=0.3). Changes in CL during follow-up were not associated with CC: TCS increased by 501 ± 63 from baseline in the 1st (upper) quartile, and by 350 ± 44, 403 ± 41 and 480 ± 56 in the 2nd, 3rd, and 4th quartiles of CL longitudinal changes (p = 0.2), respectively. Baseline TCS and its changes were not correlated with baseline CL and its changes. New calcified lesions were diagnosed in 132 (28.2%) out of the 467 patients available for this analysis, without significant difference between groups (p=0.4). Multivariate analysis demonstrated that only baseline TCS (p < 0.001), body mass index (p = 0.007) and age (p = 0.006) were independent predictors for the TCS changes.
Longitudinal CL changes do not seem to have a measurable effect on the rate of progression of CC.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Arterial calcification is a well-recognized complication of advanced atherosclerosis. Chronic kidney disease (CKD) is characterized by significantly more pronounced, disseminated and fast-progressing calcification of the vascular system, including the coronary arteries. New computed tomography-based imaging techniques allow for the noninvasive assessment and monitoring of calcification in different vascular sites. Coronary artery calcification (CAC) develops early in the course of CKD and is tightly associated with mineral and bone disorders, which include but are not limited to secondary hyperparathyroidism. In this review, recent data on the pathogenesis of CAC development and progression are discussed, with a special emphasis on fibroblast growth factor 23 and its co-receptor, klotho. The prevalence, progression and prognostic significance of CAC are reviewed separately for patients with end-stage renal disease treated with dialysis, kidney transplant recipients and patients with earlier stages of CKD. In the last section, therapeutic considerations are discussed, with special attention paid to the importance of treatment that addresses mineral and bone disorders of CKD.
    World Journal of Cardiology (WJC) 04/2014; 6(4):115-129. DOI:10.4330/wjc.v6.i4.115 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, silica–manganese oxide (Mn3O4) nanocomposites with core–shell structure were synthesized using surfactant and cosurfactant in the sol–gel reaction medium for the formation of spherical silica nanoparticles at basic condition using NH4OH as a catalyst. In order to prepare the composites of silica and Mn3O4, the aqueous solution of manganese nitrate, cetyltrimethylammonium bromide (CTAB) and tert-butanol (t-butanol) was added into the sol–gel reaction solution after the formation of silica particles which would be negative-charged at basic condition. CTAB and t-butanol as binders induced the attractive interaction between silica and Mn(OH)2 by their adsorption onto the surface of Mn(OH)2 formed by the reaction between Mn nitrate and NH4OH. After the Mn(OH)2 particles were prepared, they were transformed into Mn3O4 through the oxidation in air due to its very high reactivity. Through this process, the silica–Mn3O4 nanocomposites with controllable core–shell structure were synthesized with the variations of volume of Mn solution and concentrations of Mn nitrate, CTAB, and t-butanol. The characterizations of the silica–Mn3O4 nanocomposites were performed using FE-SEM, TEM, EDS, XRD, and TGA. The magnetization of composites was studied using a vibrating sample magnetometer (VSM) at room temperature in the range of −5000 to 5000Oe.
    Colloids and Surfaces A Physicochemical and Engineering Aspects 10/2011; 390(1):199-206. DOI:10.1016/j.colsurfa.2011.09.028 · 2.35 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Data describing relationships between change in risk factors and coronary artery calcification (CAC) are lacking and could inform optimal cardiovascular disease prevention and treatment strategies. This study aimed to examine how change in traditional cardiometabolic risk factors related to change in CAC among individuals with detectable subclinical atherosclerosis. Latent growth modeling was used to examine change in cardiometabolic risk factors (waist circumference, body mass index, systolic and diastolic blood pressure, high- and low-density lipoprotein cholesterol, triglycerides, and glucose) related to change in CAC up to an average 4.9-year follow-up in a multi-ethnic cohort of 3398 asymptomatic individuals (57.8% men) who had detectable CAC (score >0) at baseline, adjusting for baseline risk factor levels and CAC values, age, gender, race/ethnicity, smoking, family history of CVD, income, and use of antihypertensive, lipid-lowering, and glucose-lowering medications. Greater declines in blood pressure (systolic and diastolic) and low-density lipoprotein cholesterol at follow-up were each associated with greater CAC progression. The observed inverse associations were attributable to greater CAC progression in participants taking antihypertensive and lipid-lowering drugs who, as expected, had declines in blood pressure and lipid levels, respectively. These inverse associations did not emerge in participants not taking these medications. Among individuals with subclinical atherosclerosis, the unexpected inverse associations observed between change in blood pressure and lipid levels with CAC progression emphasize the importance of considering medication use, and, when feasible, the severity and duration of disease, in exploring associations between risk factors and CAC change.
    International journal of cardiology 03/2014; 174(1). DOI:10.1016/j.ijcard.2014.03.137 · 6.18 Impact Factor

Full-text (2 Sources)

Available from
Nov 12, 2014